

ABSTRACT OF THE INVENTION

The present invention relates to the use of molecules capable of specifically binding a urokinase plasminogen activator receptor (uPAR) as diagnostic reagents for the detection of metastases *in vivo*. Such metastases can include, but are not limited to, micrometastases.

10

15

20

25

30

35